Porcine Circovirus Vaccination Regimen Bypassing Maternal Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PCV vaccination strategies in pig herds are hindered by maternally derived immunity, which can interfere with the efficacy of vaccines in piglets, particularly affecting the timing and age of vaccination, leading to reduced humoral immune response and vaccine effectiveness.
Innovation Solution
A novel vaccination regimen involving vaccinating sows at weaning and their piglets between 2 to 7 weeks of age, providing a unique dose of vaccine that bypasses the interference from maternally-derived immunity and ensures effective protection against PCV infection and associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If piglets are vaccinated against PCV at early age, then protection against PCV infection is provided, but maternally derived immunity interferes with the efficacy of the vaccine
Solution Approach 1:
The patent applies preliminary action by vaccinating sows before they give birth to piglets. This timing ensures that the vaccine is administered when maternally derived immunity levels are still developing, allowing the piglet vaccine to effectively stimulate active humoral immunity without significant interference from maternal antibodies.
Solution Approach 2:
The patent employs a dynamic vaccination strategy where the timing of piglet vaccination is optimized based on the natural decline of maternally derived immunity. By vaccinating piglets at specific ages (2-7 weeks), the regimen adapts to the changing immune status of the piglets, ensuring maximum vaccine efficacy as maternal antibody levels decrease.
2Reliability
If vaccination timing is adjusted to avoid maternally derived immunity interference, then vaccine effectiveness is improved, but the complexity of vaccination strategy increases
Solution Approach 1:
The patent segments the vaccination strategy into two distinct components: (1) sow vaccination at a standardized timing before farrowing, and (2) piglet vaccination at standardized age ranges. This segmentation simplifies the overall regimen by establishing clear, separate protocols for each generation, making implementation more manageable despite the need for precise timing.
Solution Approach 2:
The patent optimizes specific parameters of the vaccination regimen, including the timing of sow vaccination relative to farrowing and the age range for piglet vaccination (2-7 weeks). By carefully selecting and standardizing these parameters, the regimen achieves high efficacy while maintaining operational simplicity through defined protocols.
3Reliability
If multiple vaccinations are administered to piglets, then protection is enhanced, but the number of vaccine doses and complexity increases
Solution Approach 1:
The patent applies partial action by administering a single dose of vaccine to piglets within the optimized age range of 2-7 weeks. This single dose is sufficient to provide effective protection because the timing is carefully selected to coincide with optimal immune responsiveness, avoiding the need for multiple doses that would increase complexity and reduce productivity.
Data Source
AI summary
The invention relates to compositions and methods for treating or preventing diseases caused by Porcine circoviruses. The invention particularly discloses methods for controlling PCV infection or disease in a pig herd, comprising (i) vaccinating sows against PCV at weaning, and (ii) vaccinating piglets against PCV at an age of between 2 to 7 weeks.